Congress Report: Results from the EMPULSE Trial

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute and Vice President of Research at Saint Luke's Health System, talks about the additional analysis from the EMPULSE trial presented at the American College of Cardiology congress.

The trial demonstrated the effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure.

Watch the Congress Report interview: Results From the EMPULSE Trial

Related Content

Medscape logo
Apr. 15, 2022

Medscape: Empagliflozin Rapidly Improves Acute Heart Failure Symptoms in Hospitalized Patients
EMPULSE trial shows treatment of patients acutely hospitalized for heart failure with empagliflozin led to a rapid incremental increase in patient well-being, compared with control patients who received placebo.
Apr. 14, 2022

HealthDay: Empagliflozin Offers Clinical Benefit in Heart Failure
A new study by Dr. Kosiborod and colleagues found clinical benefits in treatment with empagliflozin for patients hospitalized with acute heart failure.
Apr. 8, 2022

TCTMD: Quality of Life Gains Within 15 Days in Acute Heart Failure with Empagliflozin: EMPULSE Analysis
A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.